Akebia Therapeutics, Inc.
AKBA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $160,180 | $194,623 | $292,484 | $211,650 |
| % Growth | -17.7% | -33.5% | 38.2% | – |
| Cost of Goods Sold | $63,177 | $74,149 | $22,496 | $81,494 |
| Gross Profit | $97,003 | $120,474 | $269,988 | $130,156 |
| % Margin | 60.6% | 61.9% | 92.3% | 61.5% |
| R&D Expenses | $37,652 | $63,079 | $165,986 | $147,852 |
| G&A Expenses | $0 | $0 | $131,901 | $165,940 |
| SG&A Expenses | $106,545 | $100,233 | $138,601 | $174,140 |
| Sales & Mktg Exp. | $0 | $100,233 | $6,700 | $8,200 |
| Other Operating Expenses | $3,278 | $3,418 | $46,180 | $72,666 |
| Operating Expenses | $147,475 | $166,730 | $350,767 | $394,658 |
| Operating Income | -$50,472 | -$46,256 | -$80,779 | -$264,502 |
| % Margin | -31.5% | -23.8% | -27.6% | -125% |
| Other Income/Exp. Net | -$18,938 | -$5,669 | -$13,447 | -$17,522 |
| Pre-Tax Income | -$69,410 | -$51,925 | -$94,226 | -$282,024 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$69,410 | -$51,925 | -$94,226 | -$282,024 |
| % Margin | -43.3% | -26.7% | -32.2% | -133.3% |
| EPS | -0.33 | -0.28 | -0.58 | -1.48 |
| % Growth | -17.9% | 51.7% | 60.8% | – |
| EPS Diluted | -0.33 | -0.28 | -0.58 | -1.48 |
| Weighted Avg Shares Out | 210,947 | 187,465 | 182,783 | 165,950 |
| Weighted Avg Shares Out Dil | 210,947 | 187,465 | 182,783 | 165,950 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $18,185 | $6,032 | $15,687 | $19,936 |
| Depreciation & Amortization | $37,504 | $37,627 | $37,697 | $37,970 |
| EBITDA | -$13,721 | -$8,266 | $3,056 | -$189,908 |
| % Margin | -8.6% | -4.2% | 1% | -89.7% |